Pharmacological Approaches to Limit Ischemic and Reperfusion Injuries of the Heart: Analysis of Experimental and Clinical Data on P2Y(12) Receptor Antagonists

Ischemic and reperfusion injuries of the heart underlie the pathogenesis of acute myocardial infarction (AMI) and sudden cardiac death. The mortality rate is still high and is 5–7% in patients with ST-segment elevation myocardial infarction. The review is devoted to pharmacological approaches to lim...

Descripción completa

Detalles Bibliográficos
Autores principales: Maslov, Leonid N., Popov, Sergey V., Mukhomedzyanov, Alexandr V., Derkachev, Ivan A., Ryabov, Vyacheslav V., Boshchenko, Alla A., Prasad, N. Rajendra, Sufianova, Galina Z., Khlestkina, Maria S., Gareev, Ilgiz
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Society of Cardiology 2022
Materias:
State of the Art Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9551227/
https://www.ncbi.nlm.nih.gov/pubmed/36217596
http://dx.doi.org/10.4070/kcj.2022.0162
_version_ 1784806049072545792
author Maslov, Leonid N.
Popov, Sergey V.
Mukhomedzyanov, Alexandr V.
Derkachev, Ivan A.
Ryabov, Vyacheslav V.
Boshchenko, Alla A.
Prasad, N. Rajendra
Sufianova, Galina Z.
Khlestkina, Maria S.
Gareev, Ilgiz
author_facet Maslov, Leonid N.
Popov, Sergey V.
Mukhomedzyanov, Alexandr V.
Derkachev, Ivan A.
Ryabov, Vyacheslav V.
Boshchenko, Alla A.
Prasad, N. Rajendra
Sufianova, Galina Z.
Khlestkina, Maria S.
Gareev, Ilgiz
author_sort Maslov, Leonid N.
collection PubMed
description Ischemic and reperfusion injuries of the heart underlie the pathogenesis of acute myocardial infarction (AMI) and sudden cardiac death. The mortality rate is still high and is 5–7% in patients with ST-segment elevation myocardial infarction. The review is devoted to pharmacological approaches to limitation of ischemic and reperfusion injuries of the heart. The article analyzes experimental evidence and the clinical data on the effects of P2Y(12) receptor antagonists on the heart’s tolerance to ischemia/reperfusion in animals with coronary artery occlusion and reperfusion and also in patients with AMI. Chronic administration of ticagrelor prevented adverse remodeling of the heart. There is evidence that sphingosine-1-phosphate is the molecule that mediates the infarct-reducing effect of P2Y(12) receptor antagonists. It was discussed a role of adenosine in the cardioprotective effect of ticagrelor.
format Online
Article
Text
id pubmed-9551227
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher The Korean Society of Cardiology
record_format MEDLINE/PubMed
spelling pubmed-95512272022-10-18 Pharmacological Approaches to Limit Ischemic and Reperfusion Injuries of the Heart: Analysis of Experimental and Clinical Data on P2Y(12) Receptor Antagonists Maslov, Leonid N. Popov, Sergey V. Mukhomedzyanov, Alexandr V. Derkachev, Ivan A. Ryabov, Vyacheslav V. Boshchenko, Alla A. Prasad, N. Rajendra Sufianova, Galina Z. Khlestkina, Maria S. Gareev, Ilgiz Korean Circ J State of the Art Review Ischemic and reperfusion injuries of the heart underlie the pathogenesis of acute myocardial infarction (AMI) and sudden cardiac death. The mortality rate is still high and is 5–7% in patients with ST-segment elevation myocardial infarction. The review is devoted to pharmacological approaches to limitation of ischemic and reperfusion injuries of the heart. The article analyzes experimental evidence and the clinical data on the effects of P2Y(12) receptor antagonists on the heart’s tolerance to ischemia/reperfusion in animals with coronary artery occlusion and reperfusion and also in patients with AMI. Chronic administration of ticagrelor prevented adverse remodeling of the heart. There is evidence that sphingosine-1-phosphate is the molecule that mediates the infarct-reducing effect of P2Y(12) receptor antagonists. It was discussed a role of adenosine in the cardioprotective effect of ticagrelor. The Korean Society of Cardiology 2022-09-26 /pmc/articles/PMC9551227/ /pubmed/36217596 http://dx.doi.org/10.4070/kcj.2022.0162 Text en Copyright © 2022. The Korean Society of Cardiology https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https://creativecommons.org/licenses/by-nc/4.0 (https://creativecommons.org/licenses/by-nc/4.0/) ) which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle State of the Art Review
Maslov, Leonid N.
Popov, Sergey V.
Mukhomedzyanov, Alexandr V.
Derkachev, Ivan A.
Ryabov, Vyacheslav V.
Boshchenko, Alla A.
Prasad, N. Rajendra
Sufianova, Galina Z.
Khlestkina, Maria S.
Gareev, Ilgiz
Pharmacological Approaches to Limit Ischemic and Reperfusion Injuries of the Heart: Analysis of Experimental and Clinical Data on P2Y(12) Receptor Antagonists
title Pharmacological Approaches to Limit Ischemic and Reperfusion Injuries of the Heart: Analysis of Experimental and Clinical Data on P2Y(12) Receptor Antagonists
title_full Pharmacological Approaches to Limit Ischemic and Reperfusion Injuries of the Heart: Analysis of Experimental and Clinical Data on P2Y(12) Receptor Antagonists
title_fullStr Pharmacological Approaches to Limit Ischemic and Reperfusion Injuries of the Heart: Analysis of Experimental and Clinical Data on P2Y(12) Receptor Antagonists
title_full_unstemmed Pharmacological Approaches to Limit Ischemic and Reperfusion Injuries of the Heart: Analysis of Experimental and Clinical Data on P2Y(12) Receptor Antagonists
title_short Pharmacological Approaches to Limit Ischemic and Reperfusion Injuries of the Heart: Analysis of Experimental and Clinical Data on P2Y(12) Receptor Antagonists
title_sort pharmacological approaches to limit ischemic and reperfusion injuries of the heart: analysis of experimental and clinical data on p2y(12) receptor antagonists
topic State of the Art Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9551227/
https://www.ncbi.nlm.nih.gov/pubmed/36217596
http://dx.doi.org/10.4070/kcj.2022.0162
work_keys_str_mv AT maslovleonidn pharmacologicalapproachestolimitischemicandreperfusioninjuriesoftheheartanalysisofexperimentalandclinicaldataonp2y12receptorantagonists
AT popovsergeyv pharmacologicalapproachestolimitischemicandreperfusioninjuriesoftheheartanalysisofexperimentalandclinicaldataonp2y12receptorantagonists
AT mukhomedzyanovalexandrv pharmacologicalapproachestolimitischemicandreperfusioninjuriesoftheheartanalysisofexperimentalandclinicaldataonp2y12receptorantagonists
AT derkachevivana pharmacologicalapproachestolimitischemicandreperfusioninjuriesoftheheartanalysisofexperimentalandclinicaldataonp2y12receptorantagonists
AT ryabovvyacheslavv pharmacologicalapproachestolimitischemicandreperfusioninjuriesoftheheartanalysisofexperimentalandclinicaldataonp2y12receptorantagonists
AT boshchenkoallaa pharmacologicalapproachestolimitischemicandreperfusioninjuriesoftheheartanalysisofexperimentalandclinicaldataonp2y12receptorantagonists
AT prasadnrajendra pharmacologicalapproachestolimitischemicandreperfusioninjuriesoftheheartanalysisofexperimentalandclinicaldataonp2y12receptorantagonists
AT sufianovagalinaz pharmacologicalapproachestolimitischemicandreperfusioninjuriesoftheheartanalysisofexperimentalandclinicaldataonp2y12receptorantagonists
AT khlestkinamarias pharmacologicalapproachestolimitischemicandreperfusioninjuriesoftheheartanalysisofexperimentalandclinicaldataonp2y12receptorantagonists
AT gareevilgiz pharmacologicalapproachestolimitischemicandreperfusioninjuriesoftheheartanalysisofexperimentalandclinicaldataonp2y12receptorantagonists

Ejemplares similares